Inhibikase Therapeutics (IKT) Other Non-Current Assets (2021 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Other Non-Current Assets of $155759.0 for Q1 2026, up 63.75% quarter-over-quarter from $95121.0 in Q4 2025.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Other Non-Current Assets for 2 consecutive years, with $155759.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets changed N/A year-over-year to $155759.0; the TTM figure through Mar 2026 stood at $155759.0 (changed N/A YoY), while the FY2025 annual figure was $95121.0, changed N/A from the prior year.
- Other Non-Current Assets rose to $155759.0 in Q1 2026 per IKT's latest filing, from $95121.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $155759.0 in Q1 2026 and bottomed at $57913.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | 1.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.00 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 307,373.00 |
| Sep 30, 2024 | 553,318.00 |
| Dec 31, 2023 | 147,445.00 |
| Mar 31, 2021 | 2,783.00 |